CVRx (CVRX) investor relations material

Market opportunity and unmet need

• Neuromodulation therapy targets a $2.2 billion annual TAM for heart failure patients with limited options, with only 2% market penetration indicating substantial growth potential.

• Heart failure affects over 6 million people in the U.S., leads to high hospitalization rates, and is projected to cost $70 billion annually by 2030, with mortality exceeding top cancers.

• Most patients experience poor quality of life despite drug therapy, with only 1%–2% reaching optimal medication doses and high discontinuation rates.

• Patients express preference for improved quality of life over extended survival.

• Barostim targets the 'forgotten middle'—patients not eligible for advanced interventions but suffering from symptoms, addressing a significant unmet need.

Clinical evidence and therapy mechanism

• Barostim modulates neurohormonal pathways by restoring baroreceptor signaling, reducing harmful neurohormone release.

• Device is implanted subcutaneously in a 30-minute procedure with a 97% complication-free rate.

• Clinical trials show doubled improvement in exercise capacity and quality of life, with a 94% patient response rate and significant symptom improvement.

• Real-world data from 306 patients showed an 85% reduction in hospitalizations post-implant.

• Ongoing studies focus on secondary benefits like arrhythmias, ejection fraction, and anti-inflammatory effects.

Go-to-market strategy and adoption

• Sales team restructured, with over 70% replaced since early 2024 and 45% of reps hired in 2025, focusing on high-opportunity centers.

• Targeting 300–400 U.S. centers with experience in advanced cardiovascular devices and strong referral networks.

• Building multi-disciplinary support in centers, including administrative and clinical champions.

• Major barriers include therapy awareness, clinical evidence, and reimbursement, addressed by ongoing awareness campaigns and evidence generation.

• Over 100 outreach events and increased focus on advanced practice providers, direct-to-consumer marketing, and replicating successful adoption models.